Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bassam Farah

Internal Medicine Woodbridge, VA Medical Doctor

NPI 1295848497 CMS profile 13763

1725 Financial Loop, Woodbridge, VA 22192

Open in the dashboard

General payments

$7,002

388 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bassam Farah of Woodbridge, VA is reported in the CMS Open Payments database as having received $7,002 across 388 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,053 49
2024 General $1,427 61
2023 General $1,060 60
2022 General $1,025 65
2021 General $1,084 69
2020 General $855 51
2019 General $498 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bassam Farah
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Bassam Farah were reported at $1,053. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Bassam Farah Internal Medicine median Middle half National median
2019 $498 $159 $48–$570 $163
2020 $855 $119 $33–$402 $114
2021 $1,084 $135 $37–$521 $132
2022 $1,025 $141 $42–$496 $149
2023 $1,060 $149 $45–$519 $160
2024 $1,427 $154 $47–$537 $164
2025 $1,053 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,061 56 payments
  2. Lilly USA, LLC $973 58 payments
  3. AbbVie, Inc. $655 44 payments
  4. Amgen Inc. $648 30 payments
  5. GlaxoSmithKline, LLC. $632 45 payments
  6. Novo Nordisk Inc $531 29 payments
  7. Merck Sharp & Dohme Corporation $398 18 payments
  8. Pfizer Inc. $315 17 payments
  9. Abbott Laboratories $189 9 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $182 9 payments
  11. Other $1,419 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,898 382 payments
  2. Education $104 6 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $518 37 payments
  2. MOUNJARO $471 26 payments
  3. UBRELVY $467 31 payments
  4. FARXIGA $462 27 payments
  5. JARDIANCE $384 24 payments
  6. Ozempic $361 20 payments
  7. RYBELSUS $345 20 payments
  8. BREZTRI $320 16 payments
  9. VERQUVO $265 3 payments
  10. EMGALITY $246 15 payments
  11. Other $6,059 330 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 70 drugs

Part D claims

3,974

Median for Internal Medicine: 777

Drug cost

$436,664

Median for Internal Medicine: $73,373

Branded share of claims

19.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Januvia Sitagliptin Phosphate Brand 78 $103,082
Jardiance Empagliflozin Brand 67 $96,466
Eliquis Apixaban Brand 44 $44,180
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 50 $36,884
Farxiga Dapagliflozin Propanediol Brand 25 $34,839
Mounjaro Tirzepatide Brand 18 $30,434
Ozempic Semaglutide Brand 14 $24,539
Xarelto Rivaroxaban Brand 17 $19,818
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 15 $4,639
Atorvastatin Calcium Generic 467 $3,605

The 10 drugs with the highest cost, of 70 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$111,390

Of which drugs: $5,003

Medicare patients

248

Average age 74

Services billed

5,006

130 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 42%
Arthritis 32%
Depression 21%
Ischemic heart disease 18%
COPD 15%
Cancer 14%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 90 90 $1,905
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 40 168 $146

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $147
$147 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $122
$122 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $120
$120 — —
XARELTO
  • Janssen Scientific Affairs, LLC $114
$114 17 —
MOUNJARO
  • Lilly USA, LLC $97
$97 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

388 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record